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The natriuretic peptide family is the prototype of cardio-
vascular hormones. The natriuretic peptide family con-
sists of atrial natriuretic peptide (ANP), brain natriuretic
peptide (BNP), and C-type natriuretic peptide (CNP).
ANP and BNP exert their biological actions via a particu-
late guanylyl cyclase A (GC-A), whereas CNP activates the
other guanylyl cyclase B (GC-B). ANP is a cardiac hor-
mone produced by the atrium. BNP first isolated from the
brain is now known to be a cardiac hormone produced by
the ventricle of the heart. CNP is the main natriuretic pep-
tide in the central nervous system and is also produced by
vascular endothelial cells, macrophages, and chondro-
cytes, indicating that CNP is a local regulator rather than
a circulating hormone. Clinical application of ANP as a
therapeutic drug for patients with congestive heart failure
started from 1995 in Japan. Measurement of plasma ANP
and BNP concentrations as diagnostic tools are also
widely used. In order to further promote the clinical appli-
cation and elucidate the physiological implication of the
natriuretic peptide system, we have developed transgenic
and knockout mice of the natriuretic peptide family.
Recently, we demonstrated that CNP is a very strong stim-
ulator of endochondral bone growth [1,2]. CNP knockout
mice are dwarf with impaired bone growth. CNP trans-
genic mice with overexpressed CNP in cartilage are elon-
gated with skeletal overgrowth. Therefore, we have tried to
rescue mice model of achondroplasia, the most common
genetic form of human dwarfism with an activated FGF
receptor 3 by CNP and successfully demonstrated that tar-
geted overexpression of CNP in cartilage counteracts their
dwarfism. CNP prevented the shortening of achondro-
plastic bones by correcting the decreased extracellular
matrix synthesis in the growth plate through inhibition of
the MAPK pathway of FGF signalling [3,4]. These results
indicate that activation of CNP/GC-B system in endo-
chondral bone formation constitutes a novel therapeutic
strategy for skeletal dysplasias including achondroplasia,
of which there was no efficient medical treatment. We are
now undergoing translational research of CNP/GC-B sys-
tem on achondroplasia and other skeletal dysplasias.
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